An FDA letter to Horizon Therapeutics dated July 17 indicated that the company’s supplemental biologics license application, or sBLA, was approved and provides for additions to the WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS, and PATIENT COUNSELING INFORMATION sections of the Prescribing Information. The Prescribing Information now states that Tepezza “may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients’ hearing before, during, and after treatment with Tepezza and consider the benefit-risk of treatment with patients.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HZNP:
- TD Cowen analysts to hold an analyst/industry conference call
- Amgen price target lowered to $275 from $325 at Jefferies
- Horizon Therapeutics publishes data from Mirror study of Krystexxa
- Horizon presents new analysis of MRI data from Uplinza Phase 3 trial
- Horizon approved in Brazil for treatment of active Thyroid Eye Disease